Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical CoTSE:4569 74 Shareholder Yield % is 9.45% as of Mar. 2026, which is 221% above its 10-year median of 2.94. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,583.07 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 972 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks better than 91.87% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Kyorin Pharmaceutical Co's Shareholder Yield % was 9.45%.
Kyorin Pharmaceutical Co (TSE:4569) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Kyorin Pharmaceutical Co Shareholder Yield % Related Terms
Kyorin Pharmaceutical Co Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Shareholder Yield % Chart
TSE:4569 vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Kyorin Pharmaceutical Co (TSE:4569) has a Shareholder Yield % of 9.45% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kyorin Pharmaceutical Co and its competitors. This is 221% above median its historical median of 2.94. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #79 out of 972 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Kyorin Pharmaceutical Co's Shareholder Yield % too high?
Kyorin Pharmaceutical Co's current Shareholder Yield % of 9.45% is 221% above median its 10-year median of 2.94. The Drug Manufacturers industry median Shareholder Yield % is 0.29. Kyorin Pharmaceutical Co's value of 9.45% is 3158.6% above this industry median. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #79 out of 972 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #79 out of 972 companies for Shareholder Yield %. This places Kyorin Pharmaceutical Co in the top 8% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.29. Kyorin Pharmaceutical Co's value of 9.45% is 3158.6% above this benchmark. While the company's 10-year median is 2.94 vs. the industry median of 0.29, Kyorin Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.29, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyorin Pharmaceutical Co's current Shareholder Yield % of 9.45% is 3158.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Shareholder Yield % is 9.45%, which is 221% above median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,583.07, compared to a current price of 円1,162.00 — trading 26.6% below its estimated fair value. The current Shareholder Yield % is 9.45%, which is 221% above median its 10-year median of 2.94 and 3158.6% above the Drug Manufacturers industry median of 0.29. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Shareholder Yield % is 9.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,162.00 is trading 26.6% below its estimated GF Value™ of 円1,583.07.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Shareholder Yield %: 9.45% (221% above median its 10-year median of 2.94)
GF Value™: 円1,583.07 vs. price of 円1,162.00 (26.6% below fair value)
Industry Position: 3158.6% above the Drug Manufacturers median (#79 of 972)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
